Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Pembrolizumab and berahyaluronidase alfa-pmph |
| Synonyms | |
| Therapy Description |
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) is a co-formulation of Keytruda (pembrolizumab) and berahyaluronidase alfa, which potentially enhances antitumor immune response (J Clin Oncol 2025 43: 16_suppl, TPS7090, NCI Drug Dictionary). Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) is FDA-approved for use in adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of Keytruda (Pembrolizumab) (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Pembrolizumab and berahyaluronidase alfa-pmph | Keytruda Qlex | MK 3475A|MK3475A|MK-3475A | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) is a co-formulation of Keytruda (pembrolizumab) and berahyaluronidase alfa, which potentially enhances antitumor immune response (J Clin Oncol 2025 43: 16_suppl, TPS7090, NCI Drug Dictionary). Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) is FDA-approved for use in adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of Keytruda (Pembrolizumab) (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06504394 | Phase II | Pembrolizumab and berahyaluronidase alfa-pmph | A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) | Recruiting | USA | TUR | POL | NZL | GBR | ESP | DEU | AUS | 3 |
| NCT06099782 | Phase II | Pembrolizumab and berahyaluronidase alfa-pmph Pembrolizumab | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | Active, not recruiting | USA | TUR | POL | NZL | FRA | AUS | ARG | 3 |
CKB BOOST